Medicine and HealthNature Communications
SMARCB1 loss activates patient-specific distal oncogenic enhancers in malignant rhabdoid tumors
N. Q. Liu, I. Paassen, et al.
This groundbreaking study by Ning Qing Liu and colleagues unveils how the loss of *SMARCB1* in malignant rhabdoid tumors leads to significant epigenetic changes, activating unique enhancer-promoter interactions with the *MYC* oncogene, revealing insights into personalized tumorigenesis in this aggressive childhood cancer.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors
J. Schmidt, J. Chiffelle, et al.
Earth Sciences
Return to rapid ice loss in Greenland and record loss in 2019 detected by the GRACE-FO satellites
I. Sasgen, B. Wouters, et al.
Medicine and Health
Post-operative fracture risk assessment following tumor curettage in the distal femur: a hybrid in vitro and in silico biomechanical approach
A. Ghouchani, G. Rouhi, et al.
Psychology
Diet, gym, supplements, or maybe it is all in your mind? A systematic review and meta-analysis of studies on placebo and nocebo effects in weight loss in adults
Ł. Kryst, P. Bąbel, et al.
